Dual mTORC1/2 inhibition by INK-128 results in antitumor activity in preclinical models of osteosarcoma
Authors:
- 1 December 2015
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 468 (1-2) , 255-261
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 27 references indexed in Scilit:
- Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcomaCancer Biology & Therapy, 2015
- Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcomaProceedings of the National Academy of Sciences, 2014
- Translational biology of osteosarcomaNature Reviews Cancer, 2014
- Osteosarcoma treatment – Where do we stand? A state of the art reviewCancer Treatment Reviews, 2014
- Molecular mechanisms of chemoresistance in osteosarcoma (Review)Oncology Letters, 2014
- New molecular insights into osteosarcoma targeted therapyCurrent Opinion in Oncology, 2013
- Chemotherapeutic adjuvant treatment for osteosarcoma: Where do we stand?European Journal of Cancer, 2011
- The Molecular Pathogenesis of Osteosarcoma: A ReviewSarcoma, 2011
- OsteosarcomaAnnals of Oncology, 2010
- Chemotherapy resistance in osteosarcoma: current challenges and future directionsExpert Review of Anticancer Therapy, 2006